1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,110 | 1,130 | 31.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.07. | ABBISKO-B's ABSK211 Inhibitor IND Application Approved by FDA | 1 | AASTOCKS | ||
| 13.07. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES IND CLEARANCE FROM THE FDA FOR ORAL SMALL MOLECULE PAN-KRAS INHIBITOR ABSK211 | 1 | HKEx | ||
| 08.07. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 08.07. | UBS Cuts ABBISKO-B TP to HKD17.5, Reiterates Buy | 2 | AASTOCKS | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 02.07. | Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance | 6 | Benzinga.com | ||
| 02.07. | AstraZeneca, Abbisko partner on lung cancer combination therapy trial | 2 | Seeking Alpha | ||
| 02.07. | ABBISKO-B Forms Strategic Partnership With AstraZeneca PLC Ordinary Shares to Advance NSCLC Clinical Research | 2 | AASTOCKS | ||
| 02.07. | Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO for NSCLC | 181 | PR Newswire | SHANGHAI, July 1, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered... ► Artikel lesen | |
| 02.07. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS AND ASTRAZENECA ENTER A STRATEGIC COLLABORATION TO CONDUCT THE CLINICAL TRIAL OF LUMIPODLIN ... | 1 | HKEx | ||
| 29.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 26.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS REPORTS PHASE II DATA OF ABSK061 IN COMBINATION WITH ABSK043 IN FGFR2-POSITIVE ADVANCED ... | 1 | HKEx | ||
| 25.06. | Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration | 4 | Forbes | ||
| 24.06. | Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact | 2 | Benzinga.com | ||
| 24.06. | Abbisko Therapeutics, Lilly Expand R&D Alliance | 5 | Contract Pharma | ||
| 24.06. | Eli Lilly reunites with Abbisko in $1.9B, multiple target R&D pact | 4 | FierceBiotech | ||
| 24.06. | Lilly inks R&D deal worth up to $1.9B with China's Abbisko | 3 | Seeking Alpha | ||
| 24.06. | Abbisko Therapeutics Deepens R&D Collaboration with Lilly | 171 | PR Newswire | SHANGHAI, June 23, 2026 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered... ► Artikel lesen | |
| 24.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS DEEPENS R&D COLLABORATION WITH LILLY | 1 | HKEx | ||
| 22.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 05.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,07 | -0,01 % | AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates | ||
| KINIKSA PHARMACEUTICALS | 74,34 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 35,720 | -0,75 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 16,520 | 0,00 % | Monte Rosa, BioAge plunge as Novo's setback casts a shadow over pipeline | ||
| EDGEWISE THERAPEUTICS | 38,430 | 0,00 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 307,93 | +0,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 | ||
| COGENT BIOSCIENCES | 38,910 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 55,89 | 0,00 % | Everest Medicines Limited: Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib | HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,030 | -3,05 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| DYNE THERAPEUTICS | 25,180 | -2,14 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 29,820 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| ERASCA | 18,150 | -2,84 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 103,39 | -3,38 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 20,330 | +0,10 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,195 | +0,06 % | Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen |
Das Unternehmen ABBISKO CAYMAN LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,040 (+3,74 %) liegt der Kurs bei 1,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.